Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 165

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1B
Chunk 165
---
)$52,478 

The accompanying notes are an integral part of these consolidated financial statements.

119

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Cash Flows

(in thousands)

Year Ended December 31,20242023Cash flows from operating activities:Net loss$(63,691)$(65,765)Adjustments to reconcile net loss to net cash used in operating activities:Share-based compensation expense10,839 11,954 Amortization of premiums and discounts on short-term investments, net(1,301)(3,136)Non-cash interest expense— 58 Non-cash lease expense460 461 Depreciation and amortization expense193 169 Changes in operating assets and liabilities:Accounts receivable(415)(3,626)Inventory1,116 (3,265)Prepaid expenses and other current assets2,814 3,603 Other non-current assets518 518 Operating lease liabilities, net(512)(502)Accounts payable and accrued liabilities(9,773)(132)Other liabilities202 — Net cash used in operating activities(59,550)(59,663)Investing activities:Purchases of property and equipment(1,654)(3,972)Purchases of short-term investments(36,482)(64,439)Maturities of short-term investments63,338 151,617 Net cash provided by investing activities25,202 83,206 Financing activities:Issuance of common stock upon exercise of stock options— 78 Proceeds from issuance under employee stock purchase plan146 408 Deferred offering costs paid for financing(16)(160)Net cash provided by financing activities130 326 Net (decrease) increase in cash, cash equivalents and restricted cash(34,218)23,869 Cash, cash equivalents and restricted cash at beginning of year62,952 39,083 Cash, cash equivalents and restricted cash at end of year$28,734 $62,952 

The accompanying notes are an integral part of these consolidated financial statements.

120

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Cash Flows (continued)

(in thousands)

Year Ended December 31,20242023Supplemental disclosure of cash flow information:Interest paid during the period$211 $230 Supplemental disclosure of non-cash activities:Deferred transaction costs included in accounts payable and accrued liabilities$